一个佛罗里达+网络中的外部暴露因子和不良心力衰竭结果:回顾性队列研究
Wenxi Huang1, Stephen E Kimmel2, Mustafa Ahmed3
1Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, 1889 Museum Road, DSIT 6004, Gainesville, FL, 32606, United States, 1 3522736533.
JMIR formative research
|August 25, 2025
概括
较高的5月气温会增加心力衰竭和死亡风险. 这项研究将环境因素与HF结果联系起来,强调需要对极端热的进一步研究
科学领域:
- 环境健康
- 心血管流行病学
- 健康的社会决定因素
背景情况:
- 在美国,心力衰竭 (HF) 再入院率呈现地域差异.
- 外部暴露因子,包括健康的社会决定因素 (SDoH),对不良HF结果的影响尚不清楚.
研究的目的:
- 研究外部暴露因子与HF再入院风险和全因死亡率之间的关联.
- 利用数据驱动的方法来确定影响HF患者结果的关键环境和社会因素.
主要方法:
- 使用OneFlorida+网络 (2016-2022) 电子健康记录 (EHR) 数据进行的回顾性队列研究.
- 将1308个外部暴露因子 (SDoH) 与基于居住县的患者电子病历数据联系起来.
- 采用了对变量选择的处罚回归和两阶段暴露全组关联研究与混合效应的后勤回归.
主要成果:
- 分析包括63,940名因HF住院的患者.
- 5月份最高体温升高与复合结局 (HF再入院和死亡率) 的风险增加显著相关 (aOR1. 04,95% CI1. 02-1. 06).
- 在不同的人口和社会经济小组中,协会保持一致.
结论:
- 五月最高气温的升高与佛罗里达州HF再接收和死亡率的增加有显著联系.
- 需要进一步研究以阐明极端热对HF结果的影响机制.
相关概念视频
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure II: Pathophysiology
38
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
38
Heart Failure III: Clinical Manifestations
43
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
43
Heart Failure I: Introduction
54
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
54
Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505


